SCHEMBL4503147

SCHEMBL4503147

NC(=S)Nc1cccc2c1-c1ccccc1-2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.53
KMT2A Q03164 5/20 0.50
ALDH1A1 P00352 4/20 0.50
MEN1 O00255 4/20 0.50
GAA P10253 3/20 0.50
KDM4E B2RXH2 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPT P10636 2/20 0.50
HSD17B10 Q99714 2/20 0.45
TP53 P04637 1/20 0.45
TYR P14679 1/20 0.45
TSHR P16473 1/20 0.45
TAS2R38 P59533 1/20 0.45
CYP1A2 P05177 4/20 0.45
CYP3A4 P08684 2/20 0.45
MAPK1 P28482 1/20 0.45
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX12 P18054 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3606589 0.82 HSD17B10 (0.44) KMT2AALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL3606587 0.81 HSD17B10 (0.43) L3MBTL1KMT2AALDH1A1MEN1GAA
SCHEMBL4503145 0.81 HSD17B10 (0.40) L3MBTL1KMT2AALDH1A1MEN1GAA
SCHEMBL28044169 0.79 MAOA (0.64) L3MBTL1KMT2AALDH1A1MEN1GAA
SCHEMBL7593748 0.79 L3MBTL1 (0.71) L3MBTL1KMT2AALDH1A1MEN1GAA
SCHEMBL11162760 0.77 L3MBTL1 (0.49) L3MBTL1KMT2AALDH1A1MEN1GAA
SCHEMBL7611314 0.76 MAPT (0.46) L3MBTL1KMT2AALDH1A1MEN1GAA
SCHEMBL9311653 0.74 SIGMAR1 (0.57) L3MBTL1KMT2AALDH1A1MEN1GAA
SCHEMBL3611245 0.74 HSD17B10 (0.51) KMT2AALDH1A1MEN1GAAKDM4E
SCHEMBL3611242 0.74 HSD17B10 (0.47) KMT2AALDH1A1MEN1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233960-A1 Kinase Inhibitors DEVGEN NV (BE) 2009-09-17 US disclosed
EP-1934181-A2 KINASE INHIBITORS Devgen NV (BE) 2008-06-25 EP disclosed
WO-2007042321-A2 KINASE INHIBITORS DEVGEN N.V. (BE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233960-A1 Kinase Inhibitors ROCK1, MAP3K1, MAP3K11 L3MBTL1 1984/4885KMT2A 3194/4885ALDH1A1 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.